

# PRODUCT INFORMATION




## Montelukast

Item No. 35779

**CAS Registry No.:** 158966-92-8  
**Formal Name:** 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropaneacetic acid

**Synonym:** MK-476  
**MF:** C<sub>35</sub>H<sub>36</sub>ClNO<sub>3</sub>S  
**FW:** 586.2  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 245, 284, 327, 359 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Montelukast is supplied as a solid. A stock solution may be made by dissolving the montelukast in the solvent of choice, which should be purged with an inert gas. Montelukast is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of montelukast in these solvents is approximately 2 mg/ml.

### Description

Montelukast is a cysteinyl leukotriene 1 (CysLT<sub>1</sub>) receptor antagonist (IC<sub>50</sub> = 4.9 nM in HEK293 cell membranes expressing the human receptor).<sup>1</sup> It is selective for CysLT<sub>1</sub> over CysLT<sub>2</sub> receptors (IC<sub>50</sub> = >10,000 nM in COS-7 cell membranes expressing the human receptor).<sup>2</sup> Montelukast inhibits bronchoconstriction induced by leukotriene D<sub>4</sub> (LTD<sub>4</sub>; Item No. 20310) in anesthetized guinea pigs (ED<sub>50</sub> = 69 nmol/kg, p.o.).<sup>3</sup> It inhibits ovalbumin-induced airway hyperresponsiveness and increases in the number of total cells and eosinophils in bronchoalveolar lavage fluid (BALF) in a mouse model of allergic asthma when administered at doses of 3 and 10 mg/kg.<sup>4</sup> Formulations containing montelukast have been used in the treatment of asthma, allergic rhinitis, and exercise-induced bronchoconstriction.

### References

1. Sarau, H.M., Ames, R.S., Chambers, J., *et al.* Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. *Mol. Pharmacol.* **56**(3), 657-663 (1999).
2. Heise, C.E., O'Dowd, B.F., Figueroa, D.J., *et al.* Characterization of the human cysteinyl leukotriene 2 receptor. *J. Biol. Chem.* **275**(39), 30531-30536 (2000).
3. Cabré, F., Carabaza, A., García, A.M., *et al.* Pharmacological profile of MEN91507, a new CysLT<sub>1</sub> receptor antagonist. *Eur. J. Pharmacol.* **451**(3), 317-326 (2002).
4. Eum, S.Y., Maghni, K., Hamid, Q., *et al.* Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse. *Am. J. Respir. Cell Mol. Biol.* **28**(1), 25-32 (2003).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/10/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM